Gray matter damage predicts the accumulation of disability 13 years later in MS

Filippi, Massimo; Preziosa, Paolo; Copetti, Massimiliano; Riccitelli, Gianna Carla; Horsfield, Mark A.; Martinelli, Vittorio; Comi, Giancarlo; Rocca, Maria A.

doi:10.1212/01.wnl.0000435551.90824.d0

Cited by 176 publications

(171 citation statements)

References 39 publications

Supporting

Mentioning

153

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, physical disability correlates with both cortical thinning of the frontal, temporal and parietal lobes [29,30,65,66] and with thalamic atrophy [26][27][28]. In addition, global GM [61,62,[65][66][67] and thalamic atrophy [28,55] have been found to predict EDSS score up to 15-20 years after diagnosis. Several studies have pointed out a correlation between GM loss in the spinal cord and physical disability and disease duration [68][69][70][71][72][73][74][75][76][77][78].…”

Section: Gm Atrophy and Disabilitymentioning

confidence: 96%

Effects of disease modifying therapies on brain and grey matter atrophy in relapsing remitting multiple sclerosis

Favaretto

Lazzarotto

Margoni

et al. 2018

Mult Scler Demyelinating Disord

View full text Add to dashboard Cite

Background: Progressive brain atrophy is a major feature of multiple sclerosis (MS) pathology and is actually considered a major determinant of the progressive accumulation of physical and cognitive disability in MS patients. Although brain atrophy may have different pathological substrates, several lines of evidence suggest that in disease modifying drug (DMD)-treated MS patients, the higher is the anti-inflammatory effect of the DMD the lower is the progression of brain volume loss, grey matter atrophy and the accumulation of disability. Areas covered: Magnetic resonance imaging (MRI)-based measurements of inflammation (focal white matter and grey matter lesions) and neurodegeneration (decrease in brain volume, cortical and deep grey matter atrophy) are currently included among the primary or secondary end-points of Phase II and III randomized clinical trials (RCT). This review summarizes literature data on the effects of DMDs on either whole brain or grey matter atrophy emerged from RCT and from post-marketing studies.

show abstract

Section: Gm Atrophy and Disabilitymentioning

confidence: 96%

Effects of disease modifying therapies on brain and grey matter atrophy in relapsing remitting multiple sclerosis

Favaretto

Lazzarotto

Margoni

et al. 2018

Mult Scler Demyelinating Disord

View full text Add to dashboard Cite

show abstract

“…33,34 Generally speaking, brain volume changes can be an important measure of tissue damage in patients with MS. 32 Indeed, baseline atrophy and high rates of subsequent volume loss are associated with cognitive impairment, fatigue and disability progression over the long term. 32,[35][36][37][38][39][40][41] In a complex disease such as MS, brain volume loss results from the sum of and interactions between various destructive pathological processes, 42 including irrever sible demyelination, and axonal and/or neuronal loss. The neurodegenerative pathology that occurs in MS is an important target for treatment; thus, MRI brain volume measures have been used in randomized clinical trials to monitor the effects of disease modifying thera pies on these parameters.…”

Section: Focal Lesionsmentioning

confidence: 99%

MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients

2015

Nat Rev Neurol

395

147

View full text Add to dashboard Cite

“…[3][4][5][6] Furthermore, structural MRI studies have shown relations between cognitive impairment and number of cortical lesions 7 , diffusion tensor imaging changes 8,9 , gray matter magnetization transfer ratio 10 and deep gray matter volume loss. 4 Cortical involvement in MS has been increasingly recognized in recent years and the presence of cortical lesions is well described both on MRI and histopathology.…”

Section: Introductionmentioning

confidence: 99%

Regional cortical thinning in multiple sclerosis and its relation with cognitive impairment: A multicenter study

et al. 2015

View full text Add to dashboard Cite

Objectives: The objectives of this paper are to compare in a multicenter setting patterns of regional cortical thickness in patients with relapsing–remitting multiple sclerosis (RRMS) and cognitive impairment (CI) and those cognitively preserved (CP), and explore the relationship between cortical thinning and cognitive performance. Methods: T1-weighted isotropic brain scans were collected at 3T from seven European centers in 60 RRMS patients and 65 healthy controls (HCs). Patients underwent clinical and neuropsychological examinations. Cortical thickness (CTh) measures were calculated using FreeSurfer (failing in four) and both lobar and vertex-based general linear model (GLM) analyses were compared between study groups. Results: Twenty (36%) MS patients were classified as CI. Mean global CTh was smaller in RRMS patients compared to HCs (left 2.43 vs. 2.53 mm, right 2.44 vs. 2.54 mm, p < 0.001). Multivariate GLM regional analysis showed significantly more temporal thinning in CI compared to CP patients. Verbal memory scores correlated to regional cortical thinning in the insula whereas visual memory scores correlated to parietal thinning. Conclusions: This multicenter study showed mild global cortical thinning in RRMS. The extent of thinning is less pronounced than previously reported. Only subtle regional differences between CI and CP patients were observed, some of which related to specific cognitive domains.

show abstract

Gray matter damage predicts the accumulation of disability 13 years later in MS

Abstract: GM damage is one of the key factors associated with long-term accumulation of disability and cognitive impairment in MS.

Cited by 176 publications

References 39 publications

Effects of disease modifying therapies on brain and grey matter atrophy in relapsing remitting multiple sclerosis

Effects of disease modifying therapies on brain and grey matter atrophy in relapsing remitting multiple sclerosis

MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients

Regional cortical thinning in multiple sclerosis and its relation with cognitive impairment: A multicenter study

Contact Info

Product

Resources

About